Tandem Diabetes Care Inc
TNDM: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| <n@ | LOCK|TD | LOCK|Bf@l>t |
Tandem Earnings: Solid Third-Quarter Performance Is Backdrop for Major Management Change
Tandem Diabetes posted third-quarter results that included revenue growth of 14% in constant currency, and gross margin that improved by 270 basis points year over year. International sales growth of 27% was particularly strong.
